Hermida Ramón C, Ayala Diana E, Khder Yasser, Calvo Carlos
Bioengineering and Chronobiology Laboratories, University of Vigo, Vigo, Spain.
Clin Ther. 2008 Jan;30(1):108-20. doi: 10.1016/j.clinthera.2008.01.012.
Approximately 3 days a month, some 15% to 20% of patients with hypertension do not recall having taken their antihypertensive medication. Individuals with this frequency of missed doses may be at increased risk for a cardiovascular event and may have a poorer long-term prognosis.
This study used ambulatory blood pressure monitoring (ABPM) to compare the blood pressure (BP)-lowering effects of valsartan and enalapril over the 24 hours after missing 1 dose in previously untreated patients with mild to moderate essential hypertension.
This was a prospective, randomized, open-label, parallel-group, blinded end-point trial in previously untreated patients (age >18 years) with mild to moderate essential hypertension (European Society of Hypertension-European Society of Cardiology guidelines: systolic BP 140-179 mm Hg or diastolic BP 90-109 mm Hg). Patients were randomly assigned to receive 16 weeks of treatment with valsartan 160 mg/d or enalapril 20 mg/d, taken on waking. ABPM was conducted for 48 consecutive hours at baseline and again after 16 weeks of therapy. Patients took a dose of their assigned treatment at the beginning of the final session of ABPM and were instructed to skip the next daily dose.
The study enrolled 148 Spanish patients (84 men, 64 women; mean [SD] age, 45.8 [10.7] years) with previously untreated hypertension. At the end of treatment, there were significant differences between groups during the first 24 hours of ABPM, starting in the final 6 hours of the dosing interval (P < 0.001). There was no significant change in BP reduction between the first and second 24-hour periods of ABPM with valsartan (-2.1/-1.4 mm Hg), whereas enalapril was associated with a significant increase in BP over this period (5.5/3.8 mm Hg; P < 0.001 vs first 24 hours; P = 0.032 vs valsartan).
In this study in previously untreated patients with mild to moderate essential hypertension, valsartan was associated with a sustained BP-lowering effect beyond the initial 24 hours after dosing, whereas enalapril was not. There was no significant change in the efficacy of valsartan in the 24 hours after a missed dose. At the doses tested, valsartan was more effective than enalapril, both during active treatment and after a missed dose.
每月约有3天,约15%至20%的高血压患者记不起自己服用过抗高血压药物。漏服药物达到这种频率的个体发生心血管事件的风险可能会增加,且长期预后可能较差。
本研究采用动态血压监测(ABPM),比较缬沙坦和依那普利在初治的轻度至中度原发性高血压患者漏服1剂药物后24小时内的降压效果。
这是一项前瞻性、随机、开放标签、平行组、双盲终点试验,研究对象为初治的(年龄>18岁)轻度至中度原发性高血压患者(欧洲高血压学会-欧洲心脏病学会指南:收缩压140-179 mmHg或舒张压90-109 mmHg)。患者被随机分配接受16周的治疗,分别为每天晨起服用缬沙坦160 mg或依那普利20 mg。在基线时和治疗16周后连续进行48小时的动态血压监测。患者在动态血压监测最后一次测量开始时服用一剂指定药物,并被要求跳过次日剂量。
该研究纳入了148例初治高血压的西班牙患者(84例男性,64例女性;平均[标准差]年龄45.8[10.7]岁)。治疗结束时,在动态血压监测的前24小时内,即给药间隔的最后6小时开始,两组之间存在显著差异(P<0.001)。使用缬沙坦时,动态血压监测的第一个24小时和第二个24小时之间的血压降低没有显著变化(-2.1/-1.4 mmHg),而在此期间依那普利与血压显著升高有关(5.5/3.8 mmHg;与第一个24小时相比,P<0.001;与缬沙坦相比,P=0.032)。
在这项针对初治的轻度至中度原发性高血压患者的研究中,缬沙坦在给药后的最初24小时之后具有持续的降压效果,而依那普利则没有。漏服一剂药物后24小时内缬沙坦的疗效没有显著变化。在测试剂量下,无论是在积极治疗期间还是漏服一剂药物后,缬沙坦都比依那普利更有效。